Sunho Biologics,Inc. (HK:2898)
:2898
Top Page
Sunho Biologics,Inc.
(2898)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$6.00
▼(-8.95% Downside)
Action:ReiteratedDate:01/30/26
The score is weighed down primarily by severe financial weakness (sharp revenue decline, large losses, and negative cash flows). Technical indicators also remain bearish with the stock trading below key moving averages and a negative MACD. Valuation offers limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Low leverage
Relatively low reported debt-to-equity gives the company more financial flexibility to endure prolonged R&D cycles and pursue financing without immediate solvency pressure. Over 2–6 months, limited leverage reduces bankruptcy risk and preserves capacity to raise growth capital if needed.
Negative Factors
Severe revenue collapse
A ~98% revenue decline is a structural red flag: it erodes core cash generation, undermines commercial viability, and limits ability to fund operations and R&D internally. Over several months this magnifies funding needs and raises execution risk for product development and commercialization plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Relatively low reported debt-to-equity gives the company more financial flexibility to endure prolonged R&D cycles and pursue financing without immediate solvency pressure. Over 2–6 months, limited leverage reduces bankruptcy risk and preserves capacity to raise growth capital if needed.
Read all positive factors
Sunho Biologics,Inc. (2898) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$970.43M
Dividend YieldN/A
Average Volume (3M)9.77K
Price to Earnings (P/E)―
Beta (1Y)-0.03
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees130
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding156,666,800
10 Day Avg. Volume6,180
30 Day Avg. Volume9,773
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.89
Price to Sales (P/S)11985.90
P/FCF Ratio-2.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sunho Biologics,Inc. Business Overview & Revenue Model
Company Description
Sunho Biologics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics that regulate immune microenvironment by modulating the innate and adaptive immune systems. It offers IAH0968, an antibod...
How the Company Makes Money
Sunho Biologics generates revenue primarily through the development and commercialization of its biologic products. The company monetizes its research and development efforts by entering into licensing agreements with pharmaceutical companies, all...
Sunho Biologics,Inc. Financial Statement Overview
Summary
Income Statement
15
Very Negative
Balance Sheet
25
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 17.00K | 38.00K | 17.53M | 1.73M | 3.22M |
| Gross Profit | 17.00K | 38.00K | 138.00K | 473.00K | 3.22M |
| EBITDA | -83.09M | -94.95M | -123.37M | -38.11M | -64.21M |
| Net Income | -82.09M | -79.97M | -132.70M | -51.99M | -70.63M |
Balance Sheet | |||||
| Total Assets | 557.88M | 560.74M | 290.45M | 70.86M | 84.95M |
| Cash, Cash Equivalents and Short-Term Investments | 441.40M | 457.28M | 210.07M | 1.82M | 10.66M |
| Total Debt | 68.24M | 41.20M | 9.07M | 11.03M | 160.86M |
| Total Liabilities | 76.62M | 48.80M | 394.56M | 72.36M | 216.50M |
| Stockholders Equity | 481.27M | 511.94M | -104.11M | -1.50M | -131.55M |
Cash Flow | |||||
| Free Cash Flow | -23.07M | -158.28M | -41.68M | -36.02M | -58.17M |
| Operating Cash Flow | 11.18M | -109.02M | -40.65M | -34.59M | -52.65M |
| Investing Cash Flow | -417.88M | -345.04M | -83.89M | -1.36M | -10.36M |
| Financing Cash Flow | -9.63M | 406.53M | 255.50M | 27.10M | 64.98M |
Sunho Biologics,Inc. Technical Analysis
Negative
6.59
Price Trends
6.48
Negative
6.77
Negative
6.84
Negative
Market Momentum
-0.01
Negative
46.98
Neutral
98.82
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2898, the sentiment is Negative. The current price of 6.59 is above the 20-day moving average (MA) of 6.40, above the 50-day MA of 6.48, and below the 200-day MA of 6.84, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 46.98 is Neutral, neither overbought nor oversold. The STOCH value of 98.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2898.
Sunho Biologics,Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$76.93B | 46.00 | 19.62% | ― | ― | ― | |
63 Neutral | HK$1.90B | 20.08 | 9.80% | ― | 5.19% | 34.68% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
46 Neutral | HK$1.66B | -5.33 | -39.41% | ― | ― | 47.42% | |
41 Neutral | HK$970.43M | -4.74 | -16.53% | ― | ― | ― |
* General Sector Average
HK:2898
Sunho Biologics,Inc.
6.39
2.01
45.89%
HK:2268
WuXi XDC Cayman, Inc.
61.15
31.35
105.20%
HK:2511
Hightide Therapeutics Inc
3.26
2.02
162.90%
HK:2149
BaTeLab Co., Ltd.
30.12
-9.48
-23.94%
Sunho Biologics,Inc. Corporate Events
Sunho Biologics Names Executive Director Jiang Xiaoling as New CEO and Chief Scientific Officer
Jan 23, 2026
Sunho Biologics, Inc. has appointed executive director Ms. Jiang Xiaoling as both chief executive officer and chief scientific officer, effective 23 January 2026, consolidating top management and RD leadership roles in a single executive. She will...
Sunho Biologics CEO and Chief Scientific Officer Dr. Yin Liusong to Step Down
Jan 19, 2026
Sunho Biologics, Inc. announced that Dr. Yin Liusong has tendered his resignation as executive director, chief executive officer and chief scientific officer, effective 28 February 2026, to pursue other personal and career opportunities. Dr. Yin h...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.